We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Next Generation Single Molecule Imaging to Transform In Vitro Diagnosis

By LabMedica International staff writers
Posted on 15 Jun 2023

A groundbreaking multi-omic platform designed for in vitro diagnosis can rapidly detect disease biomarkers, leading to earlier diagnoses for a variety of life-threatening illnesses. More...

The state-of-the-art platform is based on SMi Systems’ (Cambridge, UK) advanced super-resolution optical technology that boasts unrivaled spatial (1.6 nanometres) and temporal (0.5 milliseconds) resolution. SMi’s automated, high-precision optical technology provides the capability to view single molecule interactions in real-time. SMi is leveraging this huge leap in optical technology to develop a diagnostic device that can identify single molecules associated with both infectious and non-infectious diseases. When paired with AI, the platform offers unparalleled quantification of disease-associated single molecules. Furthermore, its capacity to simultaneously differentiate between various diseases from a single sample and process hundreds of samples in mere minutes makes it a highly efficient diagnostic tool. SMi has developed proof-of-principle instruments and also demonstrated their effectiveness in detecting infectious diseases.

Single molecule resolution enables diseases to be detected much earlier. The resolution levels offered by SMi's technology are unprecedented and can be tailored to any molecular target, allowing individual particles to be visualized and counted directly for the first time. This offers clinicians undeniable proof of the existence of molecules associated with either infectious or non-infectious diseases. The fully automated system requires less than a second per sample to provide a diagnosis, marking a considerable improvement over less precise lateral flow tests and PCR tests that can take several minutes or even hours. With the ability to process up to 384 samples in just a few minutes, this technology could become a game-changer, particularly for large-scale patient sample screenings in healthcare settings.

“We’ve proved the success of our new platform in both respiratory diseases and cancer biomarker diagnosis, but we’re only just scratching the surface of what is possible using our single molecule imaging technology,” said Dr Andrew Thompson, Chief Executive Officer (CEO) at SMi.

Related Links:
SMi Systems 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Electrolyte Analyzer
BKE-B
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.